Bioventus (NASDAQ:BVS) Issues Earnings Results

Bioventus (NASDAQ:BVS) posted its quarterly earnings results on Thursday. The company reported $0.24 earnings per share for the quarter, FiscalAI reports. The firm had revenue of $157.90 million for the quarter. Bioventus had a net margin of 1.39% and a return on equity of 26.38%.

Here are the key takeaways from Bioventus’ conference call:

• Delivered a strong finish to 2025 with 10% organic revenue growth in Q4, Adjusted EBITDA up $8M to $37M and Adjusted EBITDA margin expanded ~490 bps to 23%, plus record quarterly cash from operations of ~ $38M (full-year cash from operations nearly $75M).
• 2026 guidance and investments target growth acceleration—management guided $600–$610M in revenue, $0.73–$0.77 adj. EPS, and $82–$87M cash from ops, while allocating ~$13M incremental investment to PNS, PRP, Ultrasonics and international to drive future revenue (PNS+PRP expected to contribute a minimum 200 bps in 2026).
• Strengthening capital structure—Q4 debt paydown of $29M left $294M outstanding and net leverage under 2.5x, with management expecting leverage <2.0x by end-2026, enabling lower interest expense and greater capital allocation optionality while targeting an ~20% Adjusted EBITDA margin in 2026.
• Near-term headwinds and assumptions—management expects Q1 to be the weakest quarter due to one fewer selling day and HA distributor inventory rebalancing, and foreign exchange drove an unplanned ~ $1M Q4 loss (~$3M+ YTD); guidance assumes no further USD fluctuations.
• Product/launch progress—pilot launches for PNS and PRP returned favorable physician and patient feedback (PNS trial and permanent solutions validated), and Ultrasonics will receive disproportionate investment (focus on spine) to expand adoption through sales, marketing, education, and evidence generation.

Bioventus Stock Up 10.7%

BVS stock traded up $0.91 during mid-day trading on Thursday, reaching $9.38. The company had a trading volume of 292,634 shares, compared to its average volume of 259,882. The firm has a fifty day simple moving average of $8.07 and a 200 day simple moving average of $7.48. The company has a debt-to-equity ratio of 1.50, a quick ratio of 1.14 and a current ratio of 1.74. The company has a market capitalization of $776.32 million, a price-to-earnings ratio of 78.17 and a beta of 0.78. Bioventus has a fifty-two week low of $5.81 and a fifty-two week high of $11.25.

Analyst Ratings Changes

Several equities analysts have recently commented on BVS shares. Cantor Fitzgerald raised Bioventus to a “strong-buy” rating in a research note on Wednesday. Barrington Research raised shares of Bioventus to a “strong-buy” rating in a research report on Monday, February 9th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Bioventus in a research note on Monday, December 29th. Two research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy”.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non?surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low?intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.